Myopic macular degeneration Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Bayer, Regeneron Pharmaceuticals, Roche

In the 7MM, the Myopic Macular Degeneration market size mainly consisted of anti-VEGF therapies and standard of care which generated nearly ~USD 734 million in 2022.

Emerging therapies for Myopic Macular Degeneration, including EYLEA (aflibercept), VABYSMO (faricimab), and others, are anticipated to drive growth in the Myopic Macular Degeneration market in the coming years.

DelveInsight has released a comprehensive report titled "Myopic Macular Degeneration - Market Insights, Epidemiology, and Market Forecast-2034," providing detailed analysis of the disease, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Myopic macular degeneration market report @ https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Myopic macular degeneration Market Report:

In 2022, the Myopic Macular Degeneration (MMD) market across the seven major markets (7MM) was largely driven by anti-VEGF therapies and standard care, generating approximately USD 734 million. Market growth is expected to be moderate during the forecast period (2023-2034) due to a relatively limited pipeline of emerging treatments.

DelveInsight reports that Japan accounted for the largest share of diagnosed MMD cases in the 7MM, representing 49% of the total, followed by the United States with roughly 27% of cases in 2022. Epidemiological data indicates that MMD disproportionately affects females across the 7MM, potentially influenced by hormonal, genetic, or environmental factors. Choroidal neovascularization (CNV), a severe complication of pathological myopia, constituted about 5% of all diagnosed MMD cases in 2022.

Leading pharmaceutical companies, including Roche, Bayer, and Regeneron Pharmaceuticals, are actively developing new therapies to address gaps in care and improve outcomes for MMD patients worldwide. DelveInsight estimates that approximately 4.1 million individuals were diagnosed with MMD across the 7MM in 2022, with numbers projected to rise during the forecast period. In the United States alone, around 1.1 million people were diagnosed with MMD in 2022, with the figure expected to grow at a notable compound annual growth rate (CAGR) through 2034.

In 2024, the U.S. FDA approved several treatments for MMD:

*
Byooviz (ranibizumab-nuna): A biosimilar to Lucentis, approved for various retinal conditions including myopic choroidal neovascularization (mCNV).

*
Cimerli (ranibizumab-eqrn): Another Lucentis biosimilar indicated for mCNV, providing a more cost-effective treatment option.

*
Susvimo (ranibizumab injection): An implantable device delivering ranibizumab continuously over six months, reducing injection frequency for patients with wet AMD and mCNV.

Key companies such as Bayer/Regeneron, Roche, and others continue to evaluate new therapies to enhance the MMD treatment landscape. Promising treatments include EYLEA (aflibercept), VABYSMO (faricimab), and additional emerging therapies.

Myopic macular degeneration Overview

Myopia is a vision condition in which distant objects appear blurred while close objects remain clear. High myopia is a more severe form of nearsightedness and significantly increases the risk of serious eye complications, such as myopic macular degeneration, posterior staphyloma, and retinal detachment, all of which can result in permanent vision loss.

As myopia progresses to pathological myopia, it creates a higher likelihood of eye complications, including Myopic Macular Degeneration (MMD). MMD involves the gradual deterioration of the macula-the central portion of the retina responsible for sharp, detailed vision. The elongation of the eyeball, thinning of the choroid, and structural changes in the retina make the macula more vulnerable to damage, resulting in MMD. Clinical features of this condition may include staphyloma, lacquer cracks, Fuchs' spots, or chorioretinal atrophy in the posterior pole of the eye.

Myopic macular degeneration Market Outlook

Myopic maculopathy, also referred to as Myopic Macular Degeneration or myopic retinopathy, encompasses conditions such as macular atrophy, lacquer cracks, and choroidal neovascularization (mCNV), with risk influenced by factors like age and axial eye length. Interventions such as low-concentration atropine and optical devices are employed to slow the progression of myopia.

At present, there is no definitive treatment for myopic maculopathy, except for managing mCNV, underscoring the pressing need for new therapeutic options. Current treatments for Myopic Macular Degeneration are largely adapted from wet age-related macular degeneration therapies, utilizing anti-VEGF agents such as LUCENTIS (whose patent has expired) and EYLEA.

Discover how the Myopic macular degeneration market is rising in the coming years @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Myopic Macular Degeneration Marketed Drugs

*
EYLEA (aflibercept): Bayer/Regeneron Pharmaceuticals

Myopic macular degeneration Emerging Drugs

*
VABYSMO (faricimab): Roche

Scope of the Myopic macular degeneration Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Myopic macular degeneration Companies: Bayer/Regeneron Pharmaceuticals, Roche, and others

*
Key Myopic macular degeneration Therapies: EYLEA (aflibercept), VABYSMO (faricimab), and others

*
Myopic macular degeneration Therapeutic Assessment: Myopic macular degeneration current marketed and Myopic macular degeneration emerging therapies

*
Myopic macular degeneration Market Dynamics: Myopic macular degeneration market drivers and Myopic macular degeneration market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Myopic macular degeneration Unmet Needs, KOL's views, Analyst's views, Myopic macular degeneration Market Access and Reimbursement

To know what's more in our Myopic macular degeneration report, visit https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Myopic macular degeneration Market Report:

*
Myopic macular degeneration market report covers a descriptive overview and comprehensive insight of the Myopic macular degeneration Epidemiology and Myopic macular degeneration market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Myopic macular degeneration market report provides insights into the current and emerging therapies.

*
The Myopic macular degeneration market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Myopic macular degeneration market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myopic macular degeneration market.

Got queries? Click here to know more about the Myopic macular degeneration market Landscape [https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Myopic macular degeneration Patient Share (%) Overview at a Glance

5. Myopic macular degeneration Market Overview at a Glance

6. Myopic macular degeneration Disease Background and Overview

7. Myopic macular degeneration Epidemiology and Patient Population

8. Country-Specific Patient Population of Myopic macular degeneration

9. Myopic macular degeneration Current Treatment and Medical Practices

10. Unmet Needs

11. Myopic macular degeneration Emerging Therapies

12. Myopic macular degeneration Market Outlook

13. Country-Wise Myopic macular degeneration Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Myopic macular degeneration Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Myopic macular degeneration Market Outlook 2034 [https://www.delveinsight.com/report-store/myopic-macular-degeneration-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Myopic macular degeneration Pipeline Insights, DelveInsight

"Myopic macular degeneration Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myopic macular degeneration market. A detailed picture of the Myopic macular degeneration pipeline landscape is provided, which includes the disease overview and Myopic macular degeneration treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopic-macular-degeneration-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-bayer-regeneron-pharmaceuticals-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.